Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Trading Update

14 Dec 2015 07:00

RNS Number : 8858I
Iofina PLC
14 December 2015
 

 

14 December 2015

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Oklahoma Operations Update

Full year production up 75% year on year

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, notes the recent decline in the Company's share price and provides the following update on the Company's iodine production in the State of Oklahoma in order to reassure and update shareholders on the Company's current operations.

 

The Board confirms that, despite production levels being impacted by downtime due to its partners' work on the Salt Water Disposal ("SWD"), coupled with recent weather-related power outages, Iofina expects to meet its forecasts and produce between 276-286 metric tonnes ("MT") of crystalline iodine in H2 2015, resulting in full year production of 570 to 580 MT of crystalline iodine (2014: 328 MT), a like-for-like increase of 75%.

As reported on 23 November 2015, the Company informed the market of actions taken by the Oklahoma Corporation Commission ("OCC") with respect to curtailing some SWD Injection Wells in areas where larger magnitude seismic activity had recently occurred. Currently Iofina's two partners are disposing of in excess of 500,000 barrels of brine water per day ("bwpd") in the Mississippi Lime play. Iofina is currently processing near 100,000 bwpd. Thus, there is an abundant source of brine in the area of the Company's production. Although seismic activity continues in Oklahoma, resulting in the OCC issuing further restrictions for some SWDs located east of the Company's production area, the Board is pleased to report that this does not directly affect the SWDs at the sites of Iofina's IOsorb® plants. 

Iofina's partners continue to expand operations in the Company's production area with relative downtime at plants IO#4 and IO#6 recently due to brine diversion for fracturing operations. Since the initial OCC restrictions, the Company has seen a decrease in brine available at IO#3 and IO#5. Although this is anticipated to continue in the near term, brine availability is expected to be only marginally down year-on-year.

The Company confirms that its other sites currently remain unaffected, but continues to consult with its partners about the possible effects of OCC restrictions. The Company expects the current reduction in injection volumes, if sustained, would result in 2016 full year production from its current plants being flat to 10% down year-on-year. The Company will update the market as this matter becomes clearer.

For the long term, Iofina is working closely with its partners to investigate other means to access brine water at its plants, which would avoid the need for direct association with particular SWDs. The Company has successfully piloted an alternative brine supply mechanism during a recent workover of one of its partner's SWDs this summer. Additionally, continued efficiencies in Iofina's process and reduction in Company costs of extraction will further mitigate the potential reduction in brine supply.

 

 

Commenting, President and CEO Tom Becker stated:

"I wish to reassure all shareholders that the Company has done all it can to mitigate further impact resulting from the seismic activity reported last month. It is encouraging that, despite this activity, the Company will achieve this year's target production figure, which is itself up 75% year-on-year.

"While there is brine loss, our production levels are expected to be broadly flat in 2016. We continue to work closely with our partners, pending the outcome of discussions with the OCC to source alternative supplies. The Board acknowledges the disappointing decline in the share price but reaffirms that that the Company is operationally robust."

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Rob Collins/Emily Morris

GMP Securities

Tel: +44(0)20 7647 2800

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFLDFDLVLIE
Date   Source Headline
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.